Breaking News

Cook General Bio To Make HemaXellerate I

By Gil Roth | November 1, 2013

Regen BioPharma signs clinical supply contract

Bio-Matrix Scientific Group's Regen BioPharma subsidiary will use Cook General Biotechnology as its CMO to make clinical supplies of HemaXellerate I. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia. The initial batches will be utilized for completing preclinical experiments requested by the FDA for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia.

"We are excited to work with the team at Regen BioPharma in producing clinical grade HemaXellerate I, initially for preclinical studies, and subsequently for the clinical trial itself," said Erik J. Woods, Ph.D., chief executive officer of Cook General Biotechnology.

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials